Skip to main content
Top
Published in: Endocrine Pathology 2/2009

01-06-2009

A Novel Complex BRAF Mutation Detected in a Solid Variant of Papillary Thyroid Carcinoma

Authors: Simion Chiosea, Marina Nikiforova, Hui Zuo, Jennifer Ogilvie, Manoj Gandhi, Raja R. Seethala, N. Paul Ohori, Yuri Nikiforov

Published in: Endocrine Pathology | Issue 2/2009

Login to get access

Abstract

BRAF gene mutations are identified in about 45% of papillary thyroid carcinomas (PTC) and represent the most common genetic event in this tumor. Here, we report a case of PTC, solid variant, with a complex BRAF mutation that involves one nucleotide substitution, C1796T, and a CTT triplet insertion, 1798_1799insCTT, located on the same allele. This mutation leads to the replacement of a threonine with an isoleucine, T599I, and replacement of a valine with an alanine and a leucine, V600delinsAL. This mutation was identified both in the preoperative fine needle aspirate sample and in the surgical specimen after total thyroidectomy. Other rare BRAF mutations in PTC are reviewed.
Literature
1.
go back to reference Fagin JA. Genetics of papillary thyroid cancer initiation: implications for therapy. Trans Am Clin Climatol Assoc 116:259–69; discussion 269–271, 2005.PubMed Fagin JA. Genetics of papillary thyroid cancer initiation: implications for therapy. Trans Am Clin Climatol Assoc 116:259–69; discussion 269–271, 2005.PubMed
2.
go back to reference Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res, 63(7):1454–7, 2003.PubMed Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res, 63(7):1454–7, 2003.PubMed
4.
go back to reference Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol, 30(2):216–22, 2006. doi:10.1097/01.pas.0000176432.73455.1b.PubMedCrossRef Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol, 30(2):216–22, 2006. doi:10.​1097/​01.​pas.​0000176432.​73455.​1b.PubMedCrossRef
5.
go back to reference Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene, 24(44):6646–56, 2005. doi:10.1038/sj.onc.1208822.PubMedCrossRef Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene, 24(44):6646–56, 2005. doi:10.​1038/​sj.​onc.​1208822.PubMedCrossRef
6.
go back to reference Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf), 65(3):364–8, 2006. doi:10.1111/j.1365-2265.2006.02605.x.CrossRef Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf), 65(3):364–8, 2006. doi:10.​1111/​j.​1365-2265.​2006.​02605.​x.CrossRef
7.
go back to reference Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab, 88(9):4393–7, 2003. doi:10.1210/jc.2003-030305.PubMedCrossRef Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab, 88(9):4393–7, 2003. doi:10.​1210/​jc.​2003-030305.PubMedCrossRef
8.
go back to reference Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab, 88(11):5399–404, 2003. doi:10.1210/jc.2003-030838.PubMedCrossRef Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab, 88(11):5399–404, 2003. doi:10.​1210/​jc.​2003-030838.PubMedCrossRef
9.
go back to reference Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M, Santisteban P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer, 13(1):257–69, 2006. doi:10.1677/erc.1.01119.PubMedCrossRef Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M, Santisteban P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer, 13(1):257–69, 2006. doi:10.​1677/​erc.​1.​01119.PubMedCrossRef
10.
go back to reference Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab, 90(12):6373–9, 2005. doi:10.1210/jc.2005-0987.PubMedCrossRef Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab, 90(12):6373–9, 2005. doi:10.​1210/​jc.​2005-0987.PubMedCrossRef
11.
go back to reference Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab, 93(10):3943–9, 2008. doi:10.1210/jc.2008-0607.PubMedCrossRef Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab, 93(10):3943–9, 2008. doi:10.​1210/​jc.​2008-0607.PubMedCrossRef
14.
go back to reference Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst, 95(8):625–7, 2003.PubMedCrossRef Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst, 95(8):625–7, 2003.PubMedCrossRef
16.
go back to reference Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio I, Fagin JA, et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab, 89(10):5175–80, 2004. doi:10.1210/jc.2003-032221.PubMedCrossRef Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio I, Fagin JA, et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab, 89(10):5175–80, 2004. doi:10.​1210/​jc.​2003-032221.PubMedCrossRef
17.
go back to reference Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol, 31(8):1256–64, 2007. doi:10.1097/PAS.0b013e3180309e6a.PubMedCrossRef Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol, 31(8):1256–64, 2007. doi:10.​1097/​PAS.​0b013e3180309e6a​.PubMedCrossRef
18.
go back to reference Trovisco V, Vieira de Castro I, Soares P, Maximo V, Silva P, Magalhaes J, et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol, 202(2):247–51, 2004. doi:10.1002/path.1511.PubMedCrossRef Trovisco V, Vieira de Castro I, Soares P, Maximo V, Silva P, Magalhaes J, et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol, 202(2):247–51, 2004. doi:10.​1002/​path.​1511.PubMedCrossRef
19.
go back to reference Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness. Virchows Arch, 446(6):589–95, 2005. doi:10.1007/s00428-005-1236-0.CrossRef Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness. Virchows Arch, 446(6):589–95, 2005. doi:10.​1007/​s00428-005-1236-0.CrossRef
22.
go back to reference Oler G, Ebina KN, Michaluart P, Jr, Kimura ET, Cerutti J. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis. Clin Endocrinol (Oxf), 62(4):509–11, 2005. doi:10.1111/j.1365-2265.2005.02235.x.CrossRef Oler G, Ebina KN, Michaluart P, Jr, Kimura ET, Cerutti J. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis. Clin Endocrinol (Oxf), 62(4):509–11, 2005. doi:10.​1111/​j.​1365-2265.​2005.​02235.​x.CrossRef
23.
go back to reference Hou P, Liu D, Xing M. Functional characterization of the T1799–1801del and A1799–1816ins BRAF mutations in papillary thyroid cancer. Cell Cycle, 6(3):377–9, 2007.PubMed Hou P, Liu D, Xing M. Functional characterization of the T1799–1801del and A1799–1816ins BRAF mutations in papillary thyroid cancer. Cell Cycle, 6(3):377–9, 2007.PubMed
24.
go back to reference Carta C, Moretti S, Passeri L, Barbi F, Avenia N, Cavaliere A, et al. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)). Clin Endocrinol (Oxf), 64(1):105–9, 2006. doi:10.1111/j.1365-2265.2005.02401.x.CrossRef Carta C, Moretti S, Passeri L, Barbi F, Avenia N, Cavaliere A, et al. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)). Clin Endocrinol (Oxf), 64(1):105–9, 2006. doi:10.​1111/​j.​1365-2265.​2005.​02401.​x.CrossRef
25.
go back to reference Trovisco V, Couto JP, Cameselle-Teijeiro J, de Castro IV, Fonseca E, Soares P, et al. Acquisition of BRAF gene mutations is not a requirement for nodal metastasis of papillary thyroid carcinoma. Clin Endocrinol (Oxf) 69:683–685, 2008.CrossRef Trovisco V, Couto JP, Cameselle-Teijeiro J, de Castro IV, Fonseca E, Soares P, et al. Acquisition of BRAF gene mutations is not a requirement for nodal metastasis of papillary thyroid carcinoma. Clin Endocrinol (Oxf) 69:683–685, 2008.CrossRef
26.
go back to reference Santarpia L, Sherman SI, Marabotti A, Clayman GL, El-Naggar AK. Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma. Hum Pathol (in press), 2009, Feb 4. Santarpia L, Sherman SI, Marabotti A, Clayman GL, El-Naggar AK. Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma. Hum Pathol (in press), 2009, Feb 4.
27.
go back to reference Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest, 115(1):94–101, 2005.PubMed Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest, 115(1):94–101, 2005.PubMed
28.
go back to reference Nikiforov YE, Erickson LA, Nikiforova MN, Caudill CM, Lloyd RV. Solid variant of papillary thyroid carcinoma: incidence, clinical–pathologic characteristics, molecular analysis, and biologic behavior. Am J Surg Pathol, 25(12):1478–84, 2001. doi:10.1097/00000478-200112000-00002.PubMedCrossRef Nikiforov YE, Erickson LA, Nikiforova MN, Caudill CM, Lloyd RV. Solid variant of papillary thyroid carcinoma: incidence, clinical–pathologic characteristics, molecular analysis, and biologic behavior. Am J Surg Pathol, 25(12):1478–84, 2001. doi:10.​1097/​00000478-200112000-00002.PubMedCrossRef
29.
go back to reference De Falco V, Giannini R, Tamburrino A, Ugolini C, Lupi C, Puxeddu E, et al. Functional characterization of the novel T599I-VKSRdel BRAF mutation in a follicular variant papillary thyroid carcinoma. J Clin Endocrinol Metab, 93(11):4398–4402, 2008.PubMedCrossRef De Falco V, Giannini R, Tamburrino A, Ugolini C, Lupi C, Puxeddu E, et al. Functional characterization of the novel T599I-VKSRdel BRAF mutation in a follicular variant papillary thyroid carcinoma. J Clin Endocrinol Metab, 93(11):4398–4402, 2008.PubMedCrossRef
Metadata
Title
A Novel Complex BRAF Mutation Detected in a Solid Variant of Papillary Thyroid Carcinoma
Authors
Simion Chiosea
Marina Nikiforova
Hui Zuo
Jennifer Ogilvie
Manoj Gandhi
Raja R. Seethala
N. Paul Ohori
Yuri Nikiforov
Publication date
01-06-2009
Publisher
Humana Press Inc
Published in
Endocrine Pathology / Issue 2/2009
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-009-9073-3

Other articles of this Issue 2/2009

Endocrine Pathology 2/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.